Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
Clinical trial NCT03249792 · TERMINATED
Trial details
- NCT number
- NCT03249792
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-20
- Primary completion
- 2023-02-22
- Enrollment
- 140
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.